Compounded semaglutide vs. brand-name: what the evidence shows

What did @msthirdgrade actually say?

She said she switched from brand-name tirzepatide (Mounjaro) to compounded semaglutide after cost became unmanageable, and the compounded version "didn't feel the same" and "almost felt like I didn't even take it." She's a long-term GLP-1 user, nearly three years on tirzepatide, who is framing this as a question about compounding quality. But she was never on branded semaglutide either, so her baseline comparison is across two entirely different drug classes.

She also conflates the brand name. She calls it "Wagovy" (Wegovy) at one point, then describes six months on it before switching to Mounjaro. The video's core premise, that compounding is the likely culprit for reduced effectiveness, may be misidentifying the real issue.

Does the science back this up?

Partially, but not for the reasons she implies. Tirzepatide and semaglutide are genuinely different drugs. Tirzepatide is a dual GIP/GLP-1 receptor agonist, while semaglutide acts only on GLP-1 receptors. Clinical trial data shows this matters for outcomes. The SURMOUNT-5 trial (Jastreboff et al., 2025, New England Journal of Medicine) compared tirzepatide directly to semaglutide in adults with obesity and found tirzepatide produced roughly 47% greater relative weight loss. The appetite suppression mechanisms also differ, which likely explains why her "food noise" experience felt different.

On compounding specifically: the FDA has not evaluated compounded semaglutide for safety or efficacy, and compounded drugs are not required to demonstrate bioequivalence to brand-name products. That's a real concern. But her reduced effect is almost certainly also explained by the drug switch itself, not just the compounding.

What did they get wrong (or right)?

She got the cost problem right. Tirzepatide without insurance can exceed $1,000 per month, and compounded semaglutide can run significantly cheaper, which is exactly why this switch is happening across millions of patients. That's a real, documented access issue.

What she got wrong, or at least incomplete, is the framing. Asking her audience whether compound semaglutide "feels the same" as Mounjaro is comparing apples to a different fruit entirely. Mounjaro is tirzepatide. Her reduced side effects and diminished food noise suppression are consistent with what head-to-head trials predict about moving from a dual agonist to a single agonist, regardless of compounding. Attributing her experience entirely to compounding quality may be inaccurate and could discourage people from a medication that might work fine for them at the right dose.

She also never confirms her compound semaglutide dosage matched a clinically standard titration schedule, which is a meaningful gap in her self-report.

What should you actually know?

Compounded semaglutide is not FDA-approved and has no required proof of bioequivalence to Wegovy or Ozempic. The FDA issued warnings in 2024 about compounded GLP-1 products, noting reports of dosing errors and adverse events, partly because some compounders use semaglutide sodium or acetate salt forms rather than the base form used in approved products. Whether this affects clinical outcomes is still being studied, but it is not a trivial difference.

If you are switching from tirzepatide to semaglutide for cost reasons, the most important thing to understand is that you are not taking a cheaper version of the same drug. You are taking a different drug. Expecting identical results is not scientifically reasonable. A prescriber who does not walk you through that distinction is doing you a disservice.